^
Association details:
| Biomarker: | Chr t(4;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | (bortezomib + Darzalex (daratumumab) + dexamethasone injection) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Published date:
08/20/2020
Excerpt:
High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities....Among a subset of patients who had received 1 prior line of therapy, treatment with D-Vd prolonged median PFS versus Vd in patients with standard cytogenetic risk (29.8 months vs 7.5 months; HR, 0.25; 95% CI, 0.15–0.42; P < 0.0001; Fig. 1c) and high cytogenetic risk (20.1 months vs 8.4 months; HR, 0.20; 95% CI, 0.06–0.62; P = 0.0026...
DOI:
10.1186/s13045-020-00948-5
Trial ID:
